Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy

BACK TO CONTENTS | PDF | PREVIOUS | NEXT

Title	Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy
Authors	Mahmood Rasool¹, Arif Malik², Muhammad Saeed Qureshi², Riaz Ahmad², Abdul Manan², Muhammad Asif³, Muhammad Imran Naseer¹ & Peter Natesan Pushparaj¹
Affiliation	¹Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, Jeddah, Saudi Arabia; ²Institute of Molecular Biology and Biotechnology (IMBB), the University of Lahore, Lahore, Pakistan; ³Department of Biotechnology and Informatics, BUITEMS, Quetta, Pakistan
Email	mahmoodrasool@yahoo.com; peter.n.pushparaj@gmail.com; *Corresponding authors
Article Type	Hypothesis
Date	Received May 30, 2014; Revised October 29, 2014; Accepted October 30, 2014; Published November 27, 2014
Abstract	Tumor lysis syndrome (TLS) is characterized by hyperuricaemia, hyperphosphatemia, hyperkalaemia, as well as hypocalcaemia due to the breakdown of tumor cells undergoing cancer therapy (chemo/radio). Therefore it is of interest to evaluate oxidative stress using selective biological markers [Malondialdehyde (MDA), Superoxide Dismutase (SOD), Glutathione (GSH) and Catalase (CAT)] in TLS. We report the marked differences (statistically significant with control) observed among a selected set of biomarkers of oxidative stress (MDA = 8.66ą1.37; SOD = 0.15ą0.11; GSH = 2.25ą.77; CAT = 0.76ą.57) in TLS patients in addition to other conventional biomarkers. Moreover, correlation was investigated among the parameters of oxidative stress and other circulating biomarkers of TLS. Data suggest the use of SOD, MDA, and GSH as potential diagnostic biomarker for TLS with other biomarkers.
Keywords	Tumor lysis syndrome (TLS); hyperuricaemia; hyperphosphatemia; hyperkalaemia; hypocalcaemia; oxidative stress; MDA; SOD; GSH.
Citation	Rasool et al. Bioinformation 10(11): 703-707 (2014)
Edited by	P Kangueane
ISSN	0973-2063
Publisher	Biomedical Informatics
License	This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.